SCHEMBL5041893

SCHEMBL5041893

O=C(NOC1CCCCO1)c1nc(-c2ccc(Cl)cc2Cl)c(-c2ccc(Cl)cc2)s1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 17/20 0.58
CNR2 P34972 2/20 0.58
HPGD P15428 2/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CCNA1 P78396 1/20 0.40
CDK5 Q00535 1/20 0.40
CDK5R1 Q15078 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5034172 0.80 CNR1 (0.67) CNR1CNR2NPC1RAB9A
SCHEMBL5041590 0.79 CNR1 (0.68) CNR1CNR2NPC1RAB9A
SCHEMBL5909570 0.79 CNR1 (0.68) CNR1CNR2NPC1RAB9A
SCHEMBL5038462 0.78 CNR1 (0.60) CNR1CNR2CDK2
SCHEMBL5043793 0.76 CNR1 (0.61) CNR1CNR2
SCHEMBL5034184 0.75 CNR1 (0.62) CNR1CNR2NPC1RAB9A
SCHEMBL5034186 0.75 CNR1 (0.62) CNR1CNR2NPC1RAB9A
SCHEMBL5038585 0.75 CNR1 (0.64) CNR1CNR2CDK2
SCHEMBL5041636 0.74 CNR1 (0.75) CNR1CNR2
SCHEMBL5038475 0.74 CNR1 (0.98) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342032-B2 Thiazole derivatives having CB1-antagonistic, agonistic or partial agonistic activity SOLVAY PHARMACEUTICALS, INC. (NL) 2008-03-11 US disclosed
US-20040266841-A1 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity ABBVIE B.V. (NL) 2004-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266841-A1 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity CNR1, CNR2, CCKAR CNR1 1/4885CNR2 2/4885HPGD 2549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.